This study examined where US adults obtain GLP-1 receptor agonists and how the source relates to compounded use and nonadherence. Data came from a National Center for Health Statistics survey of 8,118 adults in July and August 2025. Past-year use was reported by 9.8% of adults, about 25.9 million, and 18.3% of users bought direct-to-consumer. Direct-to-consumer buying was linked to compounded use (adjusted odds ratio, aOR, 14.56) and insurance nonpayment (aOR 8.01). It was also linked to cost-attributed nonadherence (aOR 4.94), but not significantly to supply-attributed nonadherence. The design is cross-sectional and self-reported, so it cannot show that acquisition channel causes these outcomes.
Why it is interesting: About one in five users bought direct-to-consumer, and 73.0% of these who knew the product status reported compounded drugs. Buying this way was linked to cost-attributed nonadherence, while the supply-attributed association was not statistically significant.
Abstract — the authors' own words, CC BY
To examine acquisition channels for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and associations with compounded use, prescription status, and nonadherence. This cross-sectional analysis used the National Center for Health Statistics Rapid Surveys System Round 7 (July-August 2025; N = 8118). Among 976 past-year users, channels were classified as clinician/pharmacy without direct-to-consumer (DTC) acquisition, any DTC telehealth/medical spa, or other. Survey-weighted logistic regression estimated adjusted odds ratios (aORs). GLP-1 RA use was reported by 9.8% of adults, approximately 25.9 million. Of users, 18.3% used a DTC or medical spa channel and 9.2% reported no clinician prescription. Among users reporting known compounded status, compounded use was 73.0% (95% CI, 62.7%-81.2%) for DTC versus 12.9% (8.8%-18.4%) for conventional acquisition (aOR, 14.56; 95% CI, 7.99-26.54). Overall, 22.6% reported compounded use and 8.6% did not know. DTC acquisition was associated with cost-attributed nonadherence (aOR, 4.94; 95% CI, 2.77-8.81); the supply-attributed association was not statistically significant (aOR, 1.15; 95% CI, 0.56-2.38; contrast P < 0.001). Associations were also observed for side-effect-attributed reduction/discontinuation (aOR, 2.12; 95% CI, 1.05-4.27) and complete discontinuation (aOR, 1.83; 95% CI, 1.01-3.32). Counseling associations were imprecise. Insurance nonpayment was associated with DTC acquisition (aOR, 8.01; 95% CI, 4.70-13.67). DTC acquisition was associated with compounded use, insurance nonpayment, and cost-attributed nonadherence. These cross-sectional findings suggest that acquisition sources and reasons for nonadherence may be useful topics for patient assessment. They do not establish causal effects of acquisition channel or demonstrate that medication records are incomplete.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.